Citadel Advisors »

Tscan Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Tscan Therapeutics (TCRX) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Tscan Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Tscan Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tscan Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2024-06-30 $924k 158k 5.85
2024-03-31 $91k 11k 7.94
2021-09-30 $99k 12k 8.30

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
NVIDIA Corporation Call Option (NVDA)
Tesla Motors Call Option (TSLA)
Apple Call Option (AAPL)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Amazon Call Option (AMZN)
Advanced Micro Devices Call Option (AMD)
Broadcom Call Option (AVGO)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Booking Holdings Call Option (BKNG)
Spdr Gold Tr Gold Shs Call Option (GLD)

View all positions for Citadel Advisors

Top funds holding Tscan Therapeutics

Lynx1 Capital Management
EcoR1 Capital
BlackRock
BlackRock
BVF
Baker Bros. Advisors
Vanguard Group
Propel Bio Management
Deer Management
Alphabet
Simplify Asset Management
Dr. Jeffrey R. Jay, M.D.
Geode Capital Management
Stempoint Capital
DC Funds

View all funds holding Tscan Therapeutics